Nitto Denko reported a bispecific siRNA design that simultaneously knocks down YAP1 and WWTR1 (TAZ), two Hippo‑pathway effectors implicated in cancer. The Molecular Therapy — Nucleic Acids paper and related commentary described target selection, delivery considerations and preclinical efficacy. By hitting two genes in the same tumor‑promoting network, the approach aims to circumvent redundancy and resistance mechanisms that limit monogenic RNA therapeutics. Biotech teams developing oligonucleotide platforms may adopt bispecific designs to expand indications where pathway backup undermines single‑target strategies.